The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1686
ISSUE1686
October 2, 2023
Valoctocogene Roxaparvovec (Roctavian) – A Gene Therapy for Severe Hemophilia A
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Valoctocogene Roxaparvovec (Roctavian) – A Gene Therapy for Severe Hemophilia A
October 2, 2023 (Issue: 1686)
Valoctocogene roxaparvovec-rvox (Roctavian –
Biomarin), an adeno-associated virus (AAV) vector-based
gene therapy, has been approved by the FDA
for one-time treatment of severe hemophilia A
in adults without pre-existing antibodies to...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.